|
1
|
Shaib YH, Davila JA, McGlynn K and
El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in
the United States: A true increase? J Hepatol. 40:472–477.
2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Saha SK, Zhu AX, Fuchs CS and Brooks GA:
Forty-year trends in cholangiocarcinoma incidence in the U.S.:
Intrahepatic disease on the rise. Oncologist. 21:594–599.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Endo I, Gonen M, Yopp AC, Dalal KM, Zhou
Q, Klimstra D, D'Angelica M, dematteo RP, Fong Y, Schwartz L, et
al: Intrahepatic cholangiocarcinoma: Rising frequency, improved
survival, and determinants of outcome after resection. Ann Surg.
248:84–96. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chou FF, Sheen-Chen SM, Chen YS, Chen MC
and Chen CL: Surgical treatment of cholangiocarcinoma.
Hepatogastroenterology. 44:760–765. 1997.PubMed/NCBI
|
|
5
|
Valle JW, Wasan H, Johnson P, Jones E,
Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, et al:
Gemcitabine alone or in combination with cisplatin in patients with
advanced or metastatic cholangiocarcinomas or other biliary tract
tumours: A multicentre randomised phase II study- the UK ABC-01
study. Br J Cancer. 101:621–627. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Okusaka T, Nakachi K, Fukutomi A, Mizuno
N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, et
al: Gemcitabine alone or in combination with cisplatin in patients
with biliary tract cancer: A comparative multicentre study in
Japan. Br J Cancer. 103:469–474. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bisello S, Buwenge M, Zamagni A, Deodato
F, Macchia G, Alessandra A, Cammelli S, Mattiucci GC, Cellini F and
Morganti AG: Chemoradiation in unresectable biliary tract cancer: A
systematic review. Hepatol Pancreat Sci 2018.
|
|
8
|
Bisello S, Buwenge M, Palloni A, Autorino
R, Cellini F, Macchia G, Deodato F, Cilla S, Brandi G, Tagliaferri
L, et al: Radiotherapy or chemoradiation in unresectable biliary
cancer: A retrospective study. Anticancer Res. 39:3095–3100.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zechlinski JJ and Rilling WS:
Transarterial therapies for the treatment of intrahepatic
cholangiocarcinoma. Semin Intervent Radiol. 30:21–27.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ray CE Jr, Edwards A, Smith MT, Leong S,
Kondo K, Gipson M, Rochon PJ, Gupta R, Messersmith W, Purcell T and
Durham J: Metaanalysis of survival, complications, and imaging
response following chemotherapy-based transarterial therapy in
patients with unresectable intrahepatic cholangiocarcinoma. J Vasc
Interv Radiol. 24:1218–1226. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Han K, Ko HK, Kim KW, Won HJ, Shin YM and
Kim PN: Radiofrequency ablation in the treatment of unresectable
intrahepatic cholangiocarcinoma: Systematic review and
meta-analysis. J Vasc Interv Radiol. 26:943–948. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Frakulli R, Buwenge M, Macchia G, Cammelli
S, Deodato F, Cilla S, Cellini F, Mattiucci GC, Bisello S, Brandi
G, et al: Stereotactic body radiation therapy in
cholangiocarcinoma: A systematic review. Br J Radiol.
92(20180688)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee J, Yoon WS, Koom WS and Rim CH:
Efficacy of stereotactic body radiotherapy for unresectable or
recurrent cholangiocarcinoma: A meta-analysis and systematic
review. Strahlenther Onkol. 195:93–102. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hutton B, Salanti G, Caldwell DM, Chaimani
A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen
JP, et al: The PRISMA extension statement for reporting of
systematic reviews incorporating network meta-analyses of health
care interventions: Checklist and explanations. Ann Intern Med.
162:777–784. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Shen ZT, Zhou H, Li AM, Li B, Shen JS and
Zhu XX: Clinical outcomes and prognostic factors of stereotactic
body radiation therapy for intrahepatic cholangiocarcinoma.
Oncotarget. 8:93541–93550. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Weiner AA, Olsen J, Ma D, Dyk P, dewees T,
Myerson RJ and Parikh P: Stereotactic body radiotherapy for primary
hepatic malignancies-Report of a phase I/II institutional study.
Radiother Oncol. 121:79–85. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Klein J, Dawson LA, Jiang H, Kim J,
Dinniwell R, Brierley J, Wong R, Lockwood G and Ringash J:
Prospective longitudinal assessment of quality of life for liver
cancer patients treated with stereotactic body radiation therapy.
Int J Radiat Oncol Biol Phys. 93:16–25. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jung DH, Kim MS, Cho CK, Yoo HJ, Jang WI,
Seo YS, Paik EK, Kim KB, Han CJ and Kim SB: Outcomes of
stereotactic body radiotherapy for unresectable primary or
recurrent cholangiocarcinoma. Radiat Oncol J. 32:163–169.
2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sebastian NT, Tan Y, Miller ED, Williams
TM and Alexandra Diaz D: Stereotactic body radiation therapy is
associated with improved overall survival compared to
chemoradiation or radioembolization in the treatment of
unresectable intrahepatic cholangiocarcinoma. Clin Transl Radiat
Oncol. 19:66–71. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kozak MM, Toesca DAS, von Eyben R, Pollom
EL and Chang DT: Stereotactic body radiation therapy for
cholangiocarcinoma: Optimizing locoregional control with elective
nodal irradiation. Adv Radiat Oncol. 5:77–84. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mahadevan A, Dagoglu N, Mancias J, Raven
K, Khwaja K, Tseng JF, Ng K, Enzinger P, Miksad R, Bullock A and
Evenson A: Stereotactic body radiotherapy (SBRT) for intrahepatic
and Hilar cholangiocarcinoma. J Cancer. 6:1099–1104.
2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Brunner TB, Blanck O, Lewitzki V,
Abbasi-Senger N, Momm F, Riesterer O, Duma MN, Wachter S, Baus W,
Gerum S, et al: Stereotactic body radiotherapy dose and its impact
on local control and overall survival of patients for locally
advanced intrahepatic and extrahepatic cholangiocarcinoma.
Radiother Oncol. 132:42–47. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liu MY, Lo CH, Lin CS, Chao HL, Yang JF,
Lin KT, Fan CY, Su YF and Huang WY: Stereotactic ablative
radiotherapy for patients with unresectable or medically inoperable
cholangiocarcinoma. Tumori. 103:236–241. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tao R, Krishnan S, Bhosale PR, Javle MM,
Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanich CW, Koay EJ, et
al: Ablative radiotherapy doses lead to a substantial prolongation
of survival in patients with inoperable intrahepatic
cholangiocarcinoma: A retrospective dose response analysis. J Clin
Oncol. 34:219–226. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Konstantinidis IT, Koerkamp BG, Do RK,
Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, Dematteo RP,
Klimstra DS, et al: Unresectable intrahepatic cholangiocarcinoma:
Systemic plus hepatic arterial infusion chemotherapy is associated
with longer survival in comparison with systemic chemotherapy
alone. Cancer. 122:758–765. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bisello S, Renzulli M, Buwenge M, Calculli
L, Sallustio G, Macchia G, Deodato F, Mattiucci G, Cammelli S,
Arcelli A, et al: An atlas for clinical target volume definition,
including elective nodal irradiation in definitive radiotherapy of
biliary cancer. Oncol Lett. 17:1784–1790. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Autorino R, Mattiucci GC, Ardito F,
Balducci M, Deodato F, Macchia G, Mantini G, Perri V, Tringali A,
Gambacorta MA, et al: Radiochemotherapy with gemcitabine in
unresectable extrahepatic cholangiocarcinoma: Long-term results of
a phase II study. Anticancer Res. 36:737–740. 2016.PubMed/NCBI
|
|
28
|
Al-Adra DP, Gill RS, Axford SJ, Shi X,
Kneteman N and Liau SS: Treatment of unresectable intrahepatic
cholangiocarcinoma with yttrium-90 radioembolization: A systematic
review and pooled analysis. Eur J Surg Oncol. 41:120–127.
2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Smart AC, Goyal L, Horick N, Petkovska N,
Zhu AX, Ferrone CR, Tanabe KK, Allen JN, Drapek LC, Qadan M, et al:
Hypofractionated radiation therapy for unresectable/locally
recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol.
27:1122–1129. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hung SP, Huang BS, Hsieh CE, Lee CH, Tsang
NM, Chang JT, Chen JS, Chou WC, Tseng JH and Hong JH: Clinical
outcomes of patients with unresectable cholangiocarcinoma treated
with proton beam therapy. Am J Clin Oncol Cancer Clin Trials.
43:180–186. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Edge BS and Compton CC: American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474.
2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bruix J, Sherman M, Llovet JM, Beaugrand
M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M
and Rodés J: EASL Panel of Experts on HCC. Clinical management of
hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL
conference. European association for the study of the liver. J
Hepatol. 35:421–430. 2001.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Schwartz LH, Litière S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar
|
